China Baicaotang Retains CCG Investor Relations

LIUZHOU CITY, Guangxi, China, Feb. 23 /PRNewswire-Asia-FirstCall/ -- China Baicaotang Medicine Limited, (OTC Bulletin Board: CNBI), ("China Baicaotang" or the "Company"), the leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceuticals and medical-related products in Guangxi Province, China, today announced that it has retained CCG Investor Relations, a global Los Angeles-based investor relations and strategic communications consulting firm to design and execute its strategic investor relations program to raise its visibility with investors worldwide.

"We look forward to developing a strong partnership with CCG Investor Relations, a firm that is uniquely qualified to accomplish our goal of raising our profile among investors globally, refining our financial communications messaging, and communicating a clear and compelling investment thesis to investors and the financial media," commented Mr. Huitian Tang, Chairman and Chief Executive Officer of China Baicaotang.

Based in southwestern China, the Company operates one of the largest regional wholesale networks in Guangxi Province supported by strategically located warehouse facilities. More than 8,000 products are distributed through its sales channels. China Baicaotang sells more than 3,200 products in its pharmacy stores, including 66 directly owned stores, under the name "Baicaotang". In addition, the Company's manufacturing unit maintains production licenses for 76 drugs, further solidifying China Baicaotang's leading market position in many major cities of Guangxi Province. For the nine months ended September 30, 2009, the Company generated revenue of $99.5 million and net income of $15.4 million.

"China Baicaotang has experienced substantial growth both organically and through a strategic acquisition in recent years, creating a unique investment thesis," commented Crocker Coulson, President of CCG Investor Relations. "China Baicaotang is well-positioned for continued growth in years ahead."

About CCG Investor Relations

CCG is a leading global investor relations and strategic communications consulting firm. In business for more than 30 years, the agency provides a complete range of investor communications, counseling, and IT and data solutions through our global network to over 300 clients across multiple capital markets. CCG has been awarded a number of industry honors for its handling of complex investor relations and crisis communications matters. The agency's corporate headquarters is in Los Angeles with additional offices in New York, Beijing, Shanghai, Hong Kong, Frankfurt, Sao Paulo and Tel Aviv. For further information, contact CCG directly, or visit the Company's web sites at http://www.ccgir.com and http://www.ccgirasia.com .

About China Baicaotang

China Baicaotang is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals and medical-related products through its subsidiaries Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited in Guangxi province, China. It operates the largest regional retail network in Guangxi province, consisting of 66 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network.

Safe Harbor Statement

This press release contains certain statements that may include "forward looking statements". All statements other than statements of historical fact included herein are "forward-looking statements". These forward looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the costs of pharmaceutical products and development, capital expenditures for equipment, increased competition in markets and those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company Contact:
     Shelly Zhang, Chief Financial Officer
     China Baicaotang Medicine Limited
     Email: [email protected]
     Tel:   +86-772-363-8318

    Investor Relations Contact:
     Elaine Ketchmere, VP of Financial Writing
     Email: [email protected]
     Tel:   +1-310-954-1345

     Mr. Crocker Coulson, President
     Email: [email protected]
     Tel:   +1-646-213-1915

     CCG Investor Relations
     Web: http://www.ccgirasia.com

SOURCE China Baicaotang Medicine Limited